Pharma Solutions Logo

Mail Us

info@pharmasolutions-int.com

Contact Us

+971 4220 7991

Linkedin-in Twitter Facebook-f
LETROZOLE (LEVALETROL)

Levaletrol (Letrozole) 2.5 mg

Lemara tablets contain an active substance called letrozole. It belongs to a group of medicines called aromatase inhibitors. It is a hormonal (or “endocrine”) breast cancer treatment. Growth of breast cancer.

Share Now

Enquire Now

Additional Information

NameLevaletrol
DescriptionLevaletrol tablets contain an active substance called Letrozole. It belongs to a group of medicines called aromatase inhibitors. It is a hormonal (or “endocrine”) breast cancer treatment. Growth of breast cancer is frequently stimulated by oestrogens which are female sex hormones. Levaletrol reduces the amount of oestrogen by blocking an enzyme (“aromatase”) involved in the production of oestrogens and therefore may block the growth of breast cancer that needs oestrogens to grow. As a consequence, tumour cells slow or stop growing and/or spreading to other parts of the body.
Active IngredientLetrozole
Indication
  • Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.
  • Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.
  • First-line treatment in postmenopausal women with hormone–dependent advanced breast cancer.
  • Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status, who have previously been treated with anti-oestrogens.
  • Neo-adjuvant treatment of postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery not indicated.
Strengths2.5 mg
Business PartnerMYLAN SAS
OriginFRANCE

 

Related Products

Related products

Disclaimer

Pharma Solution is the marketing agent and Distributor for the listed products for the Gulf and MENA region. The products are either registered and approved by the  respective local health authority or contracted by the MAH to supply to the end users  on a named patient basis. Some products such  as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.